Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Revvity, Inc. Q1 2026 Earnings Call Summary

2026-05-05
Moby summary of Revvity, Inc.'s Q1 2026 earnings call

Revvity (RVTY) Q1 2026 Earnings Transcript

2026-05-05
Prahlad Singh: Thank you, Steve, and good morning, everyone. First, I'm really excited to report that Revvity delivered strong first quarter results with 3% total company organic growth, demonstrating the resilience and strength of our business. The better-than-anticipated revenue and margin performance in the quarter led to our adjusted earnings per share in the quarter being $1.06, which was solidly above the $1.02 to the $1.04 outlook that was implied in our guidance.

RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution

2026-05-05
Revvity beat Q1 EPS and revenue estimates as 3% organic growth and portfolio execution offset margin pressure and China ImmunoDx divest plans.

Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics

2026-05-05
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Revvity Q1 Earnings Call Highlights

2026-05-05
Revvity (NYSE:RVTY) reported first-quarter 2026 results that came in ahead of its expectations and outlined a planned divestiture of its immunodiagnostics business in China, a move management said will sharpen the company’s focus and improve growth and profitability metrics going forward. First-qua

Revvity (NYSE:RVTY) Beats Q1 CY2026 Sales Expectations

2026-05-05
Life sciences company Revvity (NYSE:RVTY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 7% year on year to $711.1 million. On the other hand, the company’s full-year revenue guidance of $2.83 billion at the midpoint came in 5.2% below analysts’ estimates. Its non-GAAP profit of $1.06 per share was 4.5% above analysts’ consensus estimates.

Revvity (RVTY) Q1 Earnings and Revenues Top Estimates

2026-05-05
Revvity (RVTY) delivered earnings and revenue surprises of +4.10% and +0.85%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Revvity, Inc. 2026 Q1 - Results - Earnings Call Presentation

2026-05-05

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

2026-05-05
Revvity, Inc. (RVTY) Q1 2026 Earnings Call May 5, 2026 7:30 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor Relations & Head of...

Revvity (NYSE:RVTY) Surprises With Q1 CY2026 Sales

2026-05-05
Life sciences company Revvity (NYSE:RVTY) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 7% year on year to $711.1 million. On the other hand, the company’s full-year revenue guidance of $2.83 billion at the midpoint came in 5.2% below analysts’ estimates. Its non-GAAP profit of $1.04 per share was 2.5% above analysts’ consensus estimates.